Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Novo Nordisk is making yet another bet on ... sets its molecules apart from the competition. Now, Septerna has the validation of a deal with Novo that is worth up to $2.2 billion across an upfront ...

Novo Nordisk said Wednesday that it will work ... a more convenient weight loss treatment to the market. Under the deal, Septerna, which specializes in making small-molecule drugs, is eligible ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery ... The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...

Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over 60 ...